$2.67T
Total marketcap
$69.66B
Total volume
BTC 49.96%     ETH 17.06%
Dominance

Pfizer Inc. PFECL.SN Stock

25512 CLP {{ price }} -3.517132% {{change_pct}}%
COUNTRY
Chile
Exchange
Santiago
Market Cap
0 CLP
LOW - HIGH [24H]
25512 - 25512 CLP
VOLUME [24H]
156 CLP
{{ volume }}
P/E Ratio
5847.35
Earnings per share
4.36 CLP

Pfizer Inc. Price Chart

Pfizer Inc. PFECL.SN Financial and Trading Overview

Pfizer Inc. stock price 25512 CLP
Previous Close 41630 CLP
Open 0 CLP
Bid 0 CLP x N/A
Ask 0 CLP x N/A
Day's Range 0 - 0 CLP
52 Week Range 0 - 343380 CLP
Volume 0 CLP
Avg. Volume 7 CLP
Market Cap N/A
Beta (5Y Monthly) 0.589084
PE Ratio (TTM) 7248.453
EPS (TTM) 4.36 CLP
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

PFECL.SN Valuation Measures

Enterprise Value 235.05B CLP
Trailing P/E 7248.453
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 1768.044
Enterprise Value/Revenue 2.529
Enterprise Value/EBITDA 5.784

Trading Information

Pfizer Inc. Stock Price History

Beta (5Y Monthly) 0.589084
52-Week Change 0%
S&P500 52-Week Change 20.43%
52 Week High 343380 CLP
52 Week Low 0 CLP
50-Day Moving Average 41630 CLP
200-Day Moving Average 41630 CLP

PFECL.SN Share Statistics

Avg. Volume (3 month) 7 CLP
Avg. Daily Volume (10-Days) 8 CLP
Shares Outstanding N/A
Float 5.64B
Short Ratio N/A
% Held by Insiders 0.034%
% Held by Institutions 70.67%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 1.61
Trailing Annual Dividend Yield 0.0038%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) April 2, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 31.25%
Operating Margin (ttm) 37.99%
Gross Margin 68.93%
EBITDA Margin 43.71%

Management Effectiveness

Return on Assets (ttm) 11.63%
Return on Equity (ttm) 31.61%

Income Statement

Revenue (ttm) 92.95B CLP
Revenue Per Share (ttm) 16.56 CLP
Quarterly Revenue Growth (yoy) -28.79%
Gross Profit (ttm) 66.23B CLP
EBITDA 40.64B CLP
Net Income Avi to Common (ttm) 29.03B CLP
Diluted EPS (ttm) 4.363
Quarterly Earnings Growth (yoy) -29.50%

Balance Sheet

Total Cash (mrq) 19.97B CLP
Total Cash Per Share (mrq) 3.54 CLP
Total Debt (mrq) 36.17B CLP
Total Debt/Equity (mrq) 35.72 CLP
Current Ratio (mrq) 1.37
Book Value Per Share (mrq) 17.887

Cash Flow Statement

Operating Cash Flow (ttm) 23.94B CLP
Levered Free Cash Flow (ttm) 17.96B CLP

Profile of Pfizer Inc.

Country Chile
State NY
City New York
Address 66 Hudson Boulevard East
ZIP 10001-2192
Phone 212 733 2323
Website https://www.pfizer.com
Industry
Sector(s)
Full Time Employees 83000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Q&A For Pfizer Inc. Stock

What is a current PFECL.SN stock price?

Pfizer Inc. PFECL.SN stock price today per share is 25512 CLP.

How to purchase Pfizer Inc. stock?

You can buy PFECL.SN shares on the Santiago exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Pfizer Inc.?

The stock symbol or ticker of Pfizer Inc. is PFECL.SN.

How many shares does Pfizer Inc. have in circulation?

The max supply of Pfizer Inc. shares is 0.

What is Pfizer Inc. Price to Earnings Ratio (PE Ratio)?

Pfizer Inc. PE Ratio is 5847.35300000 now.

What was Pfizer Inc. earnings per share over the trailing 12 months (TTM)?

Pfizer Inc. EPS is 4.36 CLP over the trailing 12 months.

Stocks Related By Sector

Stocks Related By Industry

Stocks Related By Marketcap